Weill Cornell Medicine

CinA protein contributes to drug tolerance in Mycobacterium tuberculosis

Weill Cornell Medicine researchers have identified a protein in Mycobacterium tuberculosis (Mtb) that contributes to drug tolerance, a phenomenon that allows bacteria to survive treatment with drugs that would normally kill them.

Read More →

Weill Cornell advances TB research with support from NIH

Tuberculosis (TB) is a wily old killer, one of the deadliest infectious diseases in history and one of the few that naturally infects only humans. Researchers at Weill Cornell Medicine have been pursuing treatments for tuberculosis caused by Mycobacterium tuberculosis (Mtb) since the 1950s, and the program continues to excel at explaining TB’s mysteries and pushing toward more effective therapies.

Read More →

Study illuminates role of gut microbes in the response to TB treatment

Gut bacteria play an important role in the body’s response to treatment for tuberculosis (TB), according to researchers at Weill Cornell Medicine and Memorial Sloan Kettering. Because current treatments for TB involve long courses of antibiotics, which are known to disrupt the balance of microbes in the gut, a better understanding of these interactions may help in predicting outcomes to therapy and suggest ways to improve it.

Read More →

Page 1 of 1 · Total posts: 3